The aim of this study was to employ flow cytometry to monitor the changes in the expression level of PTPRG in the white blood cells (WBCs) of CML patients at the time of diagnosis and following treatment with TKIs. Here, PTPRG is linked to chronic myelogenous leukemia, BCR-ABL1 positive.